Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hepatitis01:25

Hepatitis

78
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
78
Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

428
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
428
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

974
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
974
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

635
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
635
Automated Microbial Diagnostics01:24

Automated Microbial Diagnostics

65
Automated diagnostic analyzers have transformed clinical microbiology by providing rapid and reliable methods for pathogen identification and antibiotic susceptibility testing. Among these systems, the Vitek 2 is widely used because it automates the traditionally labor-intensive processes of microbial identification (ID) and antibiotic susceptibility testing (AST), delivering standardized and timely results that are essential for effective patient care.Microbial Identification with ID CardsThe...
65
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

18
Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion...
18

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

An evaluation of the necessity of repeat testing of critical and dangerous values in a medical center in Taiwan.

Laboratory medicine·2026
Same author

An evidence gap map of digital health interventions for enhancing patient engagement in healthcare.

NPJ digital medicine·2026
Same author

Interpretable Machine Learning Framework for Predicting Major Adverse Cardiovascular Events in Rheumatoid Arthritis Using Electronic Health Records: Multicenter Cohort Study.

JMIR formative research·2026
Same author

A TriNetX global collaborative network retrospective cohort study on the impact of COVID-19 vaccination on juvenile idiopathic arthritis.

Scientific reports·2026
Same author

Predicting Pediatric Mortality Across Five Intensive Care Units: Toward an Early Warning Using Machine Learning.

Studies in health technology and informatics·2026
Same author

AI-Integrated EEG Decision Support for Neurocritical Care: A Conceptual and Feasibility Framework.

Studies in health technology and informatics·2026

Related Experiment Video

Updated: Apr 26, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

12.8K

Workflow-embedded automation improves hepatitis B screening and safety in b/tsDMARD users.

Meng Hsuan Kuo1, Chih-Wei Tseng2,3, Chih-Wei Huang4

  • 1Department of Pharmacy, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Chia-Yi, Taiwan.

BMC Infectious Diseases
|April 24, 2026
PubMed
Summary

Implementing a clinical decision support system (CDSS) significantly improved hepatitis B virus (HBV) screening rates before starting disease-modifying antirheumatic drugs (DMARDs), reducing HBV reactivation risks. Future systems need automated monitoring and prophylaxis enforcement.

Keywords:
Antirheumatic agentsHepatitis B virus reactivationMass screeningPatient safetyRheumatic diseasesWorkflow-embedded CDSS

More Related Videos

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K

Related Experiment Videos

Last Updated: Apr 26, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

12.8K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

6.6K

Area of Science:

  • Rheumatology
  • Hepatology
  • Health Informatics

Background:

  • Suboptimal adherence to hepatitis B virus (HBV) screening before initiating biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) increases reactivation risk.
  • Guideline-mandated universal screening is not consistently followed, necessitating improved strategies.

Purpose of the Study:

  • To evaluate the impact of a workflow-embedded clinical decision support system (CDSS) on HBV screening rates.
  • To assess the effect of CDSS integration on HBV reactivation and hepatitis flares in patients starting b/tsDMARDs.

Main Methods:

  • Retrospective study of 1,909 adults initiating b/tsDMARD therapy from 2004-2024.
  • Comparison of three stages: baseline, education, and workflow-integrated CDSS.
  • CDSS automatically verified HBV serologic status and generated orders for missing screenings.

Main Results:

  • HBV screening completion, including the two- and three-marker panels, significantly increased with CDSS implementation (93% and 90% respectively).
  • Hepatitis B virus reactivation (HBVr) rates decreased from 5.2% to 1.5%, and hepatitis flares decreased from 1.9% to 0.2%.
  • Antiviral prophylaxis and HBV DNA monitoring remain underutilized.

Conclusions:

  • Workflow-embedded CDSS achieved near-universal HBV screening, substantially reducing HBVr and flares.
  • Future systems require enhanced long-term monitoring and stricter adherence to prophylactic guidelines to mitigate residual risk.